Spine Art DIGITAL

Target: Spineart SA, Geneva, Switzerland Research date: 28 October 2026 Domain: Digital Evidence period: 2020–2026, with historical corporate context where relevant.

Enterprise Technology Stack & Vendor Relationships

Corporate identity and technology activities

Spineart SA describes itself as a Switzerland-based medical technology business established in Geneva in 2005, supplying spinal surgery implants and enabling technologies to surgeons and hospitals across more than 60 countries.¹

Spineart’s disclosed technology activities include medical implant development, digitally enabled surgical navigation, robotic assistance, 3D-printed implants and surgical training.¹

The company identifies eCential Robotics and SpinEM Robotics as technology partners associated with robotic spinal surgery and navigation.¹

Digital technology supplier - eCential Robotics

Spineart announced a long-term technology collaboration with eCential Robotics in December 2022, later identifying the company’s Op.n platform as the robotic navigation system compatible with Spineart’s PERLA applications.^{2, 3}

The documented arrangement involves Spineart’s spinal implants and surgical applications operating with eCential Robotics’ navigation and robotic-assisted platform.^{3, 4}

eCential Robotics independently lists Spineart among the implant manufacturers cooperating with its surgical technology platform.⁵

Integration scope

Spineart’s current enabling-technologies documentation describes navigation compatibility, surgical planning, patient movement compensation, robotic screw placement and integration of PERLA implants and instruments.⁶

The published system description includes a robotic arm with seven degrees of freedom, semi-automated screw planning and automated and collaborative operating modes.⁶

The technology is presented as a surgical workflow system used with spine implants rather than a general-purpose cybersecurity or enterprise cloud platform.⁶

Israeli-origin cybersecurity and enterprise vendors

No public evidence identified of Spineart holding a contract or licence with Check Point, Wiz, SentinelOne, CyberArk, NICE, Verint, Claroty or Palo Alto Networks in the reviewed corporate technology disclosures.^{1, 6}

No public evidence identified of an Israeli-origin cybersecurity product forming a documented component of the PERLA and Op.n collaboration.^{3, 5}

Procurement and systems integration

Spineart and eCential Robotics are identified as the relevant technology developers in the published surgical platform announcements; the sources do not identify a separate Israeli technology integrator.^{3, 5}

No public evidence identified of a named Israeli systems integrator engaged by Spineart for enterprise transformation or infrastructure services.^{1, 6}

Corporate ownership relevant to vendor attribution

Gimv announced in June 2020 that it was Spineart’s largest shareholder and that EGS Beteiligungen AG had become a cornerstone investor alongside management shareholders following a CHF 50 million investment.⁷

On 26 September 2025, Spineart announced a further CHF 25 million capital increase backed by Gimv and EGS Beteiligungen AG.⁸

Gimv continued to identify Spineart as a portfolio investment on its official company page in 2026.⁹

The examined investor announcements do not disclose current individual voting percentages for all Spineart shareholders.^{7, 8}

No public evidence identified of an Israeli enterprise technology supplier relationship attributable to the named investors through Spineart’s disclosed operational technology collaborations.^{1, 9}

Surveillance, Biometrics & Retail Technology

Facial recognition and biometrics

Spineart’s published surgical technology portfolio concerns spinal implants, navigation and robotic-assisted surgery.⁶

No public evidence identified of Spineart deploying Israeli-origin facial recognition, gait identification or biometric retail analytics products in its disclosed technology portfolio.^{1, 6}

Predictive analytics and workforce monitoring

Spineart’s published privacy statement describes analysis of website visitor behavior, including cookies, browsing activity and associated technical information.¹⁰

The privacy statement identifies visitor analytics as one purpose of personal-data processing but does not identify the analytics vendor.¹⁰

No public evidence identified of Israeli-origin predictive policing, employee surveillance or intelligence-monitoring products being used by Spineart in the reviewed public technology and privacy disclosures.^{6, 10}

Third-party deployment

Spineart’s privacy statement permits disclosure of personal data to third-party companies undertaking hosting, technical maintenance, analytics and communications services.¹⁰

The statement does not identify those processors by legal name, and therefore does not establish the nationality of the relevant technology vendors.¹⁰

No public evidence identified of Israeli-origin surveillance technology being supplied indirectly through Spineart’s named surgical robotics partners.^{3, 5}

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Personal-data collection

Spineart’s published privacy statement identifies collection of names, contact information, professional details, recruitment information, geographical preferences and certain IP addresses.¹⁰

The statement also describes collection through contact forms, email communications, website browsing and cookies.¹⁰

Spineart identifies responding to enquiries, managing applications, training registration and analyzing website behavior as purposes of processing.¹⁰

Data storage and processing

Spineart’s privacy statement states that information may be processed in countries where the company has facilities, service providers, partners or agents, including the United States.¹⁰

It describes contractual safeguards for international transfers, including standard contractual clauses where applicable.¹⁰

The privacy statement does not identify the physical data centres, cloud tenants, hosting providers or exact storage regions used for website information.¹⁰

The retrieved material does not establish whether patient imaging data processed by eCential’s surgical platform is retained centrally, transmitted to Spineart, stored within hospital infrastructure or processed using external cloud services.^{3, 6}

Israeli data residency

No public evidence identified establishing that Spineart’s website data, customer records or surgical application data are hosted in Israel.^{10, 6}

No public evidence identified identifying an Israeli-domiciled company as a data processor for Spineart’s disclosed digital systems.^{5, 10}

Data centres

No public evidence identified of Spineart owning, leasing or operating a data centre in Israel in the reviewed company infrastructure and technology disclosures.^{1, 11}

Government cloud and Project Nimbus

No public evidence identified of Spineart participating in Project Nimbus or supplying cloud infrastructure to Israeli state bodies in its published corporate technology and partnership disclosures.^{1, 8}

No public evidence identified of Spineart marketing sovereign-cloud services or digital sovereignty infrastructure to Israeli military or civilian government institutions.^{6, 8}

Temporal status

The published privacy statement records its last update as 12 January 2021, so the disclosed processing categories constitute historical published policy information rather than independently verified October 2026 infrastructure inventory.¹⁰

Spineart’s 2026 technology materials confirm continuing commercialization of digitally enabled surgical systems but do not disclose their complete data-processing architecture.^{6, 3}

Defence, Intelligence & Security Sector Technology Relationships

Military and intelligence contracts

Spineart’s disclosed robotic platform collaboration identifies eCential Robotics as the technology partner and documents medical applications involving spinal surgery.^{3, 4}

No public evidence identified of a Spineart technology contract with the Israel Defense Forces, Israeli Ministry of Defence or Israeli intelligence organizations in the reviewed corporate partnership announcements.^{3, 4}

Documented civilian clinical deployment

On 25 July 2024, Spineart reported that Providence St. Joseph Hospital in Orange, California, had performed spinal procedures using an eCential Robotics platform with Spineart-compatible implants.¹²

The announcement identifies Providence St. Joseph Hospital as the clinical institution, eCential Robotics as the robotic platform provider and Spineart as the compatible implant provider.¹²

The hospital was described as the first clinical institution using the relevant robotic system, with a documented deployment in the United States.¹²

Dual-use technology

Spineart’s 2026 enabling-technologies materials describe automatic registration, navigation, patient movement compensation and robotic-assisted screw placement for medical procedures.⁶

These functions are documented as surgical capabilities, and the cited materials do not establish military or intelligence deployment.^{6, 12}

No public evidence identified of the PERLA surgical applications or eCential Op.n platform being supplied by Spineart for Israeli military surveillance or operational intelligence use.^{3, 12}

Offensive cyber

No public evidence identified of Spineart developing, selling or licensing offensive cyber tools, exploit frameworks, surveillance interception systems or digital weapons in its disclosed corporate technology portfolio.^{1, 6}

Israeli commercial presence

A historical version of Spineart’s company website included Israel among the markets served, but the current reviewed company profile does not identify an Israeli military technology customer or Israeli software contract.^{13, 1}

The historical geographical listing cannot establish the date, recipient, value or exact category of any Israel-related transaction.¹³

Constructive-notice period

Spineart publicly announced continued development of surgical navigation and robotic applications after 19 July 2024, including the August 2026 PERLA regulatory announcement.^{3, 12}

No public evidence identified in those announcements of a continuing Israeli military technology provision arrangement after July or November 2024.^{3, 12}

Settlement-related deployment

No public evidence identified establishing that Spineart’s navigation applications, surgical software or robotic technology were deployed in Israeli settlements or supplied to settlement-based Israeli government institutions.^{1, 6}

Israeli commercial presence - historical company-controlled publication. A historical search-indexed version of Spineart’s official homepage contained the heading “+60 markets”, followed by a country list explicitly including “Israel” between “Ireland” and “Italy”. The accompanying corporate description stated: “We support spine surgeons in over 60 markets”. The indexed material also contained company news dated 5 June 2025, establishing that the indexed page content incorporated information from at least that date. Spineart SA’s legal notices identify the company and its Digital Communication Department as the website publisher. The historical listing therefore represents evidence of company-controlled presentation of Israel as a served market, rather than a distributor-only assertion or incidental geographical reference. However, no independently accessible, timestamped archive capture of the exact listing was verified, so its precise publication date remains unestablished.^{14, 15}

Historical listing - observation and continuity limits. Through 28 October 2026, the earliest and latest independently verified observation dates for the Israel-inclusive homepage version could not be established. Search-indexed historical content retains the explicit Israel listing, but the available indexing metadata does not provide a sufficiently precise, independently reproducible observation date. The current homepage, examined on 28 October 2026, displays a redesigned corporate presentation without the historical country-by-country market list. Spineart’s current company profile continues to describe operations across more than 60 countries without individually identifying Israel. This establishes that the historical list was absent from the examined current homepage; it does not establish when it disappeared, whether other company-controlled pages continued publishing it, or whether Spineart ceased serving the Israeli market. The remaining publicly discoverable association is the historical indexed company-controlled market listing.^{14, 13, 1}

Archived publication and cessation - evidence limitations. 2020–28 October 2026 - no public evidence identified establishing a first or last dated archive capture of the specific Israel-inclusive listing, a documented withdrawal announcement, a dated replacement of that listing, or verified commercial cessation. Searches covered historical homepage indexing, company-controlled market statements, the current homepage, the current corporate profile, and Internet Archive retrieval routes. Attempts to open timestamped Wayback material did not return a verifiable archived page. No reliable first-publication date, last-publication date, or cessation date can therefore be assigned.^{14, 13, 1, 16}

2020–28 October 2026 - no additional independently dated public evidence identified: renewed searches for Spineart’s historical “+60 markets” country list returned a search-index record displaying “Israel” between “Ireland” and “Italy”, but opening the indexed URL redirected to Spineart’s redesigned homepage, which no longer displays that list. The search result’s relative publication and crawl ages do not establish independently reproducible calendar dates for the historical content. The current corporate profile confirms operations in more than 60 countries without individually naming Israel. Neither page establishes when the country list was first published or removed. The newly examined evidence therefore does not resolve the previously documented dating limitations.^{13, 1}

2020–28 October 2026 - no public evidence identified: additional checks examined Internet Archive timestamped replay and CDX retrieval routes, the Common Crawl public index service, and searches for the distinctive historical country sequence restricted to periods before 2024 and 2025. No accessible, timestamped primary capture containing the Israel-inclusive list was obtained. Common Crawl’s publicly accessible index interface establishes a potential verification route, but no matching historical crawl record was independently recovered. The earliest and latest verified publication dates, removal date, and any cessation of Israeli market activity remain undetermined.^{13, 17}

AI, Algorithmic & Autonomous Systems

Surgical navigation and automation

Spineart’s enabling-technologies portfolio includes computer-assisted navigation, robotic instruments and semi-automated surgical planning.⁶

The published robotic platform description includes automatic registration, patient movement compensation and navigated screw placement.⁶

The public documentation does not establish that these functions use a specific machine-learning model, neural-network architecture or training dataset.⁶

PERLA regulatory milestones

On 13 March 2025, Spineart announced US FDA 510(k) clearance for the PERLA TL application used with eCential Robotics’ Op.n navigation platform.¹⁸

The companies described integration of Spineart’s PERLA TL Open and minimally invasive screw systems with navigation-specific interfaces and navigated surgical instruments.¹⁸

On 26 August 2026, Spineart and eCential Robotics announced additional US FDA 510(k) clearance extending the PERLA TL application to robotic-assisted procedures.³

The 2026 announcement describes the combination of implant technology, real-time navigation and robotic assistance within an integrated surgical workflow.³

State-sector AI provision

No public evidence identified of Spineart supplying AI or computer-vision systems to Israeli military, intelligence or state security agencies in the reviewed public technology announcements.^{3, 6}

Training data

No public evidence identified of Spineart training machine-learning systems on intercepted communications, civilian surveillance records or population datasets originating in Israel or occupied Palestinian territories.^{6, 10}

Autonomous systems

The verified autonomous and semi-automated features are described in connection with medical screw planning and placement.⁶

No public evidence identified of Spineart designing or supplying autonomous target generation, combat tracking or lethal decision-support software.^{3, 6}

Technology Ecosystem & R&D Footprint

Technology development and research

Spineart’s public corporate profile identifies internal research and development capabilities supporting implants, navigation and robotic technologies.¹

On 27 June 2024, Spineart announced the appointment of Laurent Nodé-Langlois as chief technology officer, with responsibility for digital surgical planning, navigation, robotics and partnerships with technology startups.¹⁹

SpinEM Robotics investment

On 30 April 2024, Spineart announced a €10 million strategic investment in SpinEM Robotics, a company developing navigation and robotic assistance technologies for spinal surgery.²

The announcement identified an intended development collaboration involving SpinEM Robotics’ navigation technology and Spineart’s surgical systems.²

The stated collaboration also referenced potential technological compatibility with the eCential Robotics open platform.²

The 2024 announcement identifies Spineart as investor and SpinEM Robotics as recipient, with the communication published on Spineart’s corporate website.²

The investment was publicly documented on 30 April 2024 and remained referenced in Spineart’s corporate partnership material in 2026; the retrieved documents do not establish a verified cessation date.^{2, 1}

eCential Robotics collaboration

Spineart’s October 2023 corporate announcement described its existing co-development agreement with eCential Robotics and ongoing work on surgical enabling technologies.²⁰

The companies continued announcing joint milestones in March 2025 and August 2026.^{18, 3}

The relationship was therefore publicly documented from at least 2022 through August 2026, with no termination disclosed in the reviewed company announcements.^{20, 3}

Dallas innovation facility

On 12 November 2024, Spineart announced the opening of its Dallas Innovation Center, a 5,500-square-foot facility incorporating training, surgical laboratory facilities and robotic technology.¹¹

The announcement identified a surgical laboratory equipped with the eCential Robotics system, combining imaging, navigation, robotics and Spineart applications.¹¹

The 2026 announcement states that Spineart’s PERLA application would be demonstrated at the Dallas Innovation Center.³

Manufacturing and development geography

Spineart’s September 2025 financing announcement identified a newly opened production facility in Reignier, France, alongside ongoing international development and regulatory programmes.⁸

No public evidence identified of Spineart operating an Israeli research laboratory, engineering facility or robotic software development office in the reviewed company infrastructure descriptions.^{1, 11}

Historical acquisition - Meditech Spine

Spineart publicly announced an agreement in 2020 to acquire Meditech Spine LLC, a United States spinal implant company, with the announced transaction expected to close in July 2020.²¹

The source establishes the announcement and intended transaction; the reviewed material does not independently verify the acquisition’s completion date.²¹

The announcement does not identify Meditech Spine as an Israeli technology company.²¹

Intellectual property

Spineart describes patented medical technologies within its portfolio and identifies intellectual property development as part of its technology strategy.^{1, 19}

No public evidence identified of a patent licensing or co-development agreement between Spineart and Technion, Hebrew University, Weizmann Institute or another specifically named Israeli research institution in the reviewed corporate materials.^{1, 19}

Civil Society Scrutiny & Regulatory History

Corporate and ownership records

Spineart’s official governance page names Jérôme Trividic as CEO and identifies co-founders Stéphane Mugnier-Jacob and Jérôme Levieux.¹

The same page identifies Bart Diels, Gautier Lefebvre, Kevin Klein, Christian Pfab, Dominik Sauter and Jean-Philippe Favre in its governance material.¹

Gimv’s 2020 announcement describes Gimv, EGS Beteiligungen and management as shareholders, without establishing each individual’s current voting percentage.⁷

The September 2025 capitalization announcement identifies Gimv and EGS Beteiligungen as participating investors.⁸

UK corporate records

UK Companies House identifies SPINEART (UK) LTD as an active company incorporated on 12 December 2012 under company number 08328402.²²

Its officer register identifies Shane Aiken, Stephan Cori, Edouard Goetgheluck and Gino Poggiali as active directors.²³

The persons-with-significant-control register identifies Gino Poggiali as an active controlling person with significant influence or control.²⁴

The same register records historical control notifications involving Jérôme Trividic, Stéphane Mugnier, Jérôme Levieux and Jérôme Ventura, with their previous control notifications marked as ceased.²⁴

The UK filing history records continuing corporate filings, including a confirmation statement filed in March 2026.²⁵

Named-principal screening record

• Jérôme Trividic - CEO: Searched Israel, defence technology, surveillance and military relationships; no public evidence identified in the reviewed corporate and technology disclosures.^{1, 3}
• Stéphane Mugnier-Jacob - co-founder: Searched Israeli cybersecurity, military technology and investment connections; no public evidence identified in the reviewed corporate and investor disclosures.^{1, 7}
• Jérôme Levieux - co-founder: Searched Israeli defence, surveillance and technology investments; no public evidence identified in the reviewed corporate and investor disclosures.^{1, 7}
• Gino Poggiali - senior executive and UK controlling person: Searched Israeli technology, defence and cybersecurity relationships; no public evidence identified in the reviewed corporate and registry documents.^{1, 24}
• Bart Diels - Gimv representative: Searched Israeli technology investments and military-related links involving Spineart; no public evidence identified in the reviewed corporate and investor disclosures.^{1, 9}
• Gautier Lefebvre - Gimv representative: Searched Israeli defence technology and surveillance investments involving Spineart; no public evidence identified in the reviewed corporate and investor disclosures.^{1, 9}
• Kevin Klein - Gimv representative: Searched Israeli cybersecurity and defence-related technology investments involving Spineart; no public evidence identified in the reviewed governance and investor materials.^{1, 9}
• Christian Pfab - EGS representative: Searched Israeli military and technology investments involving Spineart; no public evidence identified in the reviewed corporate and financing disclosures.^{1, 8}
• Dominik Sauter - EGS representative: Searched Israeli surveillance, technology and military investments involving Spineart; no public evidence identified in the reviewed corporate and financing disclosures.^{1, 8}
• Jean-Philippe Favre - minority shareholder representative: Searched Israeli technology and military investment connections; no public evidence identified in the reviewed company governance materials.¹
• Laurent Nodé-Langlois - CTO: Searched Israeli robotic navigation, military technology and surveillance; no public evidence identified in the reviewed technology appointment and partnership announcements.^{19, 3}
• Stephan Cori - finance executive and UK director: Searched Israel, defence and technology investments; no public evidence identified in the reviewed governance and UK registration documents.^{1, 23}
• Shane Aiken - UK director: Searched Israeli technology procurement and defence relationships; no public evidence identified in the reviewed UK corporate records.²³
• Edouard Goetgheluck - UK director: Searched Israeli technology, surveillance and defence relationships; no public evidence identified in the reviewed UK corporate records.²³
• Alessia Erlingher - commercial executive: Searched Israeli technology sales, defence and surveillance relationships; no public evidence identified in the reviewed corporate governance and technology announcements.^{1, 23}
• Guillaume Amblard - product executive: Searched Israeli technology partnerships and military applications; no public evidence identified in the reviewed corporate and product disclosures.^{1, 6}
• Max Lok - regulatory executive: Searched Israeli digital technology approvals and state contracts; no public evidence identified in the reviewed governance and regulatory announcements.^{1, 3}
• Yohan Stalder - operations executive: Searched Israeli technology suppliers and military-related procurement; no public evidence identified in the reviewed company disclosures.^{1, 8}
• Jérôme Ventura - historical UK controlling person: Searched Israeli technology and defence connections; no public evidence identified in the reviewed historical control record.²⁴

Named group and partner screening record

• Spineart SA - target: Israeli digital technology suppliers, state technology contracts and settlement deployment searched; no public evidence identified in the reviewed corporate technology disclosures.^{1, 6}
• SPINEART (UK) LTD - operating affiliate: Israeli technology procurement and digital service relationships searched; no public evidence identified in the reviewed corporate filings.^{22, 25}
• Spineart USA Inc. - named US operating entity: Israeli technology and defence procurement searched; no public evidence identified in the reviewed US corporate announcement.²¹
• Gimv - institutional investor: Israeli defence technology relationships attributable to Spineart searched; no public evidence identified in the reviewed investment documentation.^{7, 9}
• EGS Beteiligungen AG - institutional investor: Israeli surveillance and defence technology relationships attributable to Spineart searched; no public evidence identified in the reviewed investment announcements.^{7, 8}
• eCential Robotics - development partner: Israeli military procurement, settlement customers and defence technology deployment searched; no public evidence identified in the reviewed partnership and product materials.^{5, 12}
• SpinEM Robotics - investment recipient: Israeli military navigation, defence procurement and settlement deployment searched; no public evidence identified in the reviewed transaction announcement.²
• Meditech Spine LLC - announced acquisition target: Israeli defence technology and surveillance connections searched; no public evidence identified in the reviewed acquisition announcement.²¹

Civil society investigations

No public evidence identified in the reviewed public corporate, NGO-directed search results or technology announcements of a named investigation specifically establishing a Spineart digital technology relationship with Israeli settlement infrastructure.^{1, 6}

Boycott and divestment

No public evidence identified of an organized campaign specifically targeting Spineart’s provision of digital technology to Israeli state institutions in the reviewed public material.^{1, 26}

Regulatory developments

Spineart announced initial regulatory clearance for PERLA TL navigation integration in March 2025 and additional clearance for robotic-assisted procedures in August 2026.^{18, 3}

Spineart also announced US FDA approval of its BAGUERA C cervical disc in August 2026, relating to a medical implant rather than Israeli digital infrastructure.²⁷

The company announced a September 2025 US commercial launch of SCARLET AC-Ti, another medical implant product.²⁸

No public evidence identified in the reviewed regulatory announcements of export-control penalties, sanctions proceedings or regulatory findings concerning Spineart technology sales to Israeli state institutions.^{18, 27}

Public communication act record

Spineart SA was the acting entity for its own announcements concerning SpinEM Robotics, with SpinEM the named investment beneficiary, Spineart’s corporate website the publishing channel, and 30 April 2024 the earliest documented announcement date; the relationship continues to appear in Spineart’s subsequent company profile, while an exact termination date is not established.^{2, 1}

Spineart SA and eCential Robotics were the acting entities for the collaboration publicly described through their corporate channels, with hospitals and spinal surgeons identified as the intended clinical users, and publicly documented milestones spanning 2022–2026.^{5, 20, 3}

Spineart SA was the acting entity for the July 2024 clinical-deployment announcement naming Providence St. Joseph Hospital as recipient institution; Spineart’s website carried the announcement, and the documented event occurred in California.¹²

Spineart SA was the acting entity for the November 2024 Dallas Innovation Center announcement, with surgeons, hospitals and academic institutions identified as intended users; subsequent 2026 announcements confirm continued presentation of its surgical technology at that facility.^{11, 3}

Spineart SA and its investors were the named participants in the September 2025 capital increase, with Gimv and EGS Beteiligungen as capital providers; the transaction was communicated through both Spineart’s and Gimv’s corporate websites.^{8, 9}

The retrieved corporate announcements establish their original publication dates and intended professional audiences but do not establish audience size, readership statistics or the complete historical duration of the webpages’ public availability.^{2, 8}